GILD34:BVMF
Gilead Sciences Inc BDR
65,69 R$
arrow_downward
-0,18%(-0,12) 1 d.
19. okt., 10:25:17 GMT-3 · BRL
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: GILD34…
Atvērt
65,69 R$
Augsta
65,69 R$
Zema
65,69 R$
Tirgus kapitalizācija
191,73 mljrd.
Vid. apjoms
319,00
Apjoms
1,00
Augstākā 52 ned.
67,38 R$
Zemākā 52 ned.
51,33 R$
Apgrozībā esošās akcijas
1,24 mljrd.
Darbinieku skaits
17 tūkst.
Atvērt
65,69 R$
Augsta
65,69 R$
Zema
65,69 R$
Tirgus kapitalizācija
191,73 mljrd.
Vid. apjoms
319,00
Apjoms
1,00
Augstākā 52 ned.
67,38 R$
Zemākā 52 ned.
51,33 R$
Apgrozībā esošās akcijas
1,24 mljrd.
Darbinieku skaits
17 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Trefis
·
pirms 23 minūtēm
What Has Changed About Owning Gilead Stock?
ad-hoc-news.de
·
pirms 1 stundas
Gilead Sciences stock: BofA lifts target for Gilead Sciences stock to USD 164.00
STAT
·
pirms 2 stundām
Pharmalittle: We're reading about Roche investments in Germany, a Gilead bowel disease drug, and more
Investing.com
·
pirms 3 stundām
Gilead to present HIV and antiviral research at IDWeek 2026
Profils
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Par “Gilead Sciences Inc BDR”
ĢenerāldirektorsDaniel O'Day
Darbinieki17 tūkst.
Dibināšanas datums1987. gada 22. jūn.
Galvenais birojsFoster City, Kalifornija, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnegilead.com